Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

GV Leads $51.7M Series C Investment In Biopharmaceutical Startup

by prnewswire.com posted 1year ago 332 views
Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that it has completed a $51.7 million Series C preferred financing led by new investor GV (formerly Google Ventures). The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors.